Katz B Z, Ishai-Michaeli R, Zusman T, Vlodavsky I, Witz I P
Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.
Invasion Metastasis. 1994;14(1-6):276-89.
Cloned BALB/c 3T3 cells transformed in vitro with polyoma virus and maintained in culture (C cells) were compared with respect to their ability to form experimental metastases, with cells from the same clones that were passaged subcutaneously in vivo (CTC cells), thereby gaining a high tumorigenicity phenotype. No correlation was found between a high subcutaneous tumorigenicity potential or the progression state of these cells, and their capacity to form experimental metastases. Both cell types were also tested for their ability to release heparan sulfate degradation products from a naturally produced, sulfate-labeled extracellular matrix (ECM). Whereas the in vitro maintained C cells did not express an endo-beta-D-glucuronidase (heparanase) activity, some of the in vivo passaged CTC cells expressed such an activity. No strict correlation was found, however, between heparanase activity and the ability of CTC cells from individual tumors to form experimental metastases. However, A9 CTC 220 cells which produced a large number of lung metastases also expressed a high heparanase activity. Both heparanase and lung colonization by A9 CTC 220 cells were inhibited to a large extent by heparin, suggesting the involvement of heparanase in the extravasation of these highly metastatic cells. A9 CTC 220 cells were found to release basic fibroblast growth factor (bFGF) from ECM. This release was partially inhibited by carrageenan lambda which also completely inhibited the heparanase activity expressed by these cells. The in vivo acquisition of heparanase activity was not a result of cell fusion between heparanase expressing host-derived cells and heparanase-negative transformed cells. This conclusion was based on the fact that both the in vitro maintained, heparanase-negative as well as the in vitro passaged, heparanase-positive cells exhibited a similar membrane and molecular market profile.
将体外经多瘤病毒转化并在培养中维持的克隆BALB/c 3T3细胞(C细胞),与来自相同克隆且在体内皮下传代从而获得高致瘤性表型的细胞(CTC细胞)在形成实验性转移的能力方面进行了比较。未发现这些细胞的高皮下致瘤潜力或进展状态与其形成实验性转移的能力之间存在相关性。还测试了这两种细胞类型从天然产生的、硫酸化标记的细胞外基质(ECM)中释放硫酸乙酰肝素降解产物的能力。体外维持的C细胞不表达内切β-D-葡糖醛酸酶(乙酰肝素酶)活性,而一些体内传代的CTC细胞表达这种活性。然而,在单个肿瘤的CTC细胞的乙酰肝素酶活性与形成实验性转移的能力之间未发现严格的相关性。然而,产生大量肺转移的A9 CTC 220细胞也表达高乙酰肝素酶活性。A9 CTC 220细胞的乙酰肝素酶和肺定植在很大程度上受到肝素的抑制,这表明乙酰肝素酶参与了这些高转移性细胞的外渗。发现A9 CTC 220细胞从ECM中释放碱性成纤维细胞生长因子(bFGF)。这种释放被λ-卡拉胶部分抑制,λ-卡拉胶也完全抑制了这些细胞表达的乙酰肝素酶活性。体内获得乙酰肝素酶活性不是表达乙酰肝素酶的宿主来源细胞与乙酰肝素酶阴性转化细胞之间细胞融合的结果。这一结论基于以下事实:体外维持的、乙酰肝素酶阴性以及体外传代的、乙酰肝素酶阳性细胞均表现出相似的膜和分子标记谱。